LQDA
Liquidia Corporation
October 1, 2026 · pre-market
- Rarity
- 2.93
- Peak move
- −20.56%
- Float cap
- $2.1B
Liquidia Corporation is a biopharmaceutical company focused on respiratory and vascular diseases such as pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. It commercializes YUTREPIA, an inhaled dry powder treprostinil, in the United States and shares profit from Sandoz's generic treprostinil injection. It also develops L606 and calls on U.S. healthcare providers involved in treatment, distribution, and reimbursement.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
10 events · 1 from SEC or newswire · 1 timed with the move- Timed with the move
analyst_ratingNeedham lowered its price target on Liquidia to $72 from $110 while maintaining a Buy rating following the Delaware court's finding that two United Therapeutics '327 patent claims are valid and infringed.
analyst_ratingBTIG downgraded Liquidia to Neutral from Buy with no price target after the Delaware court ruled that Liquidia infringed two claims of United Therapeutics' '327 patent, noting the final remedy could include an immediate stop for YUTREPIA across indications until PH-ILD is removed from the label.
analyst_ratingBofA lowered its price target on Liquidia to $40 from $92 while keeping a Neutral rating, citing increased uncertainty over Yutrepia's commercial prospects after the adverse patent ruling, with the PH-ILD indication representing about half of current Yutrepia sales.
- Key event
patent_eventThe U.S. District Court for the District of Delaware found claims 1 and 14 of United Therapeutics' '327 patent, covering treatment of PH-ILD with inhaled treprostinil, valid and infringed by Liquidia's YUTREPIA, while the remaining asserted claims were invalid; the parties must submit a proposed form of judgment within one week.
analyst_ratingNeedham analyst Serge Belanger maintained a Buy rating on Liquidia but cut his price target to $70 from $110, factoring in a 50% royalty burden on PH-ILD revenue after the court found Yutrepia infringes two valid claims of United Therapeutics' '327 patent.
- Key event
peer_disclosureUnited Therapeutics said it believes it is entitled to an order instructing the FDA to withdraw approval of Liquidia's Yutrepia NDA under 35 U.S.C. § 271(e)(4)(A) after the Delaware court found Liquidia induces infringement of claims 1 and 14 of the '327 patent, and intends to seek monetary damages including a royalty on past Yutrepia sales.
- Key event
executive_remarkLiquidia CEO Roger Jeffs said the company respectfully disagrees with the Delaware court's decision on claims 1 and 14 of United Therapeutics' '327 patent and is prepared to pursue all appellate options, and that Liquidia intends to submit a supplement to YUTREPIA's New Drug Application to remove PH-ILD from the label.
analyst_ratingCantor Fitzgerald analyst Olivia Brayer Saunders said United Therapeutics' path to $1,000 'just got easier' after the ruling that Yutrepia infringes the two key '327 patent claims, maintaining an Overweight rating and $700 price target on UTHR.
analyst_ratingLifeSci Capital reiterated a Hold rating on Liquidia on September 30, 2026, and Raymond James maintained its Buy rating on the same date, per analyst rating data.
trading_haltLiquidia Technologies shares were halted on volatility on September 30, 2026, amid unconfirmed chatter of a negative ruling in the company's case against United Therapeutics.